{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T12:48:04Z","timestamp":1775911684763,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.critrevonc.2026.105176","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T16:31:07Z","timestamp":1770395467000},"page":"105176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The RAS testing in real world management of metastatic colorectal cancer: The results of Italian Laboratories Survey"],"prefix":"10.1016","volume":"221","author":[{"given":"Carmine","family":"Pinto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Malapelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Fassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evaristo","family":"Maiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Sartore-Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Annibali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7158-2605","authenticated-orcid":false,"given":"Nicola","family":"Normanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105176_bib1","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.annonc.2023.06.011","article-title":"ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe","volume":"34","author":"Bayle","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105176_bib2","first-page":"264","article-title":"Interpreting and integrating genomic tests results in clinical cancer care: overview and practical guidance","volume":"74","author":"Casolino","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105176_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105176_bib4","unstructured":"Cetuximab Summary of Product Characteristics, n.d."},{"key":"10.1016\/j.critrevonc.2026.105176_bib5","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/jclinpath-2014-202404","article-title":"Guidance for laboratories performing molecular pathology for cancer patients","volume":"67","author":"Cree","year":"2014","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105176_bib6","unstructured":"I. NUMERI D.E.L. CANCRO I.N. ITALIA 2024 P AS S I Progressi nelle Aziende Sanitarie per la Salute in Italia, n.d."},{"key":"10.1016\/j.critrevonc.2026.105176_bib7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1470-2045(13)70552-7","article-title":"A Bill of Rights for patients with cancer in Europe","volume":"15","author":"Lawler","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105176_bib8","unstructured":"LINEE GUIDA TUMORI DEL COLON | AIOM [WWW Document], n.d. URL \u3008https:\/\/www.aiom.it\/linee-guida-aiom-2024-tumori-del-colon\/\u3009 (Accessed 2.3.25)."},{"key":"10.1016\/j.critrevonc.2026.105176_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104574","article-title":"Detecting BRAF mutations in colorectal cancer in clinical practice: an Italian experts\u2019 position paper","volume":"206","author":"Malapelle","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105176_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.32074\/1591-951X-895","article-title":"The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists\u2019 perspective","author":"Malapelle","year":"2023","journal-title":"Pathologica"},{"key":"10.1016\/j.critrevonc.2026.105176_bib11","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s41591-022-01717-2","article-title":"Delivering precision oncology to patients with cancer","volume":"28","author":"Mateo","year":"2022","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2026.105176_bib12","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105176_bib13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2022.09.005","article-title":"Access and quality of biomarker testing for precision oncology in Europe","volume":"176","author":"Normanno","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105176_bib14","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/annonc\/mdv176","article-title":"Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial","volume":"26","author":"Normanno","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105176_bib15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrclinonc.2009.111","article-title":"Implications for KRAS status and EGFR-targeted therapies in metastatic CRC","volume":"6","author":"Normanno","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105176_bib16","unstructured":"Panitumumab SUMMARY OF PRODUCT CHARACTERISTICS, n.d."},{"key":"10.1016\/j.critrevonc.2026.105176_bib17","unstructured":"Raccomandazioni AIOM e SIAPEC-IAP per la valutazione delle mutazioni di RAS nel carcinoma del colon-retto \u2013 SIAPeC-IAP [WWW Document], n.d. URL \u3008https:\/\/www.siapec.it\/2014\/04\/01\/raccomandazioni-aiom-e-siapec-iap-per-la-valutazione-delle-mutazioni-di-ras-nel-carcinoma-del-colon-retto\/\u3009 (Accessed 7.19.23)."},{"key":"10.1016\/j.critrevonc.2026.105176_bib18","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4023-4","article-title":"NSCLC molecular testing in Central and Eastern European countries","volume":"18","author":"Ryska","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105176_bib19","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/annonc\/mdz082","article-title":"Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial","volume":"30","author":"Santos","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105176_bib20","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"33","author":"Van Cutsem","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105176_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/annonc\/mdz005","article-title":"Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy","volume":"30","author":"Vidal","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105176_bib22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/annonc\/mdx707","article-title":"The European Society for Medical Oncology (ESMO) Precision Medicine Glossary","volume":"29","author":"Yates","year":"2018","journal-title":"Ann. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:51:17Z","timestamp":1775908277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826000636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":22,"alternative-id":["S1040842826000636"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105176","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The RAS testing in real world management of metastatic colorectal cancer: The results of Italian Laboratories Survey","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105176"}}